• Home
  • NEW DAY MEDICINE
  • 4 (78) 2025
  • 128 -4 (78) 2025 - Sanokulova S.A. - IMMUNOLOGICAL INDICATORS OF THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS

128 -4 (78) 2025 - Sanokulova S.A. - IMMUNOLOGICAL INDICATORS OF THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS

IMMUNOLOGICAL INDICATORS OF THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS

Sanokulova S.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis characterized by progressive renal failure, leading to high morbidity and mortality rates. The underlying mechanisms of HRS involve complex interactions between hemodynamic changes, systemic inflammation, and immune dysregulation. Immunological factors, particularly pro-inflammatory cytokines and immune cell alterations, play a crucial role in the pathogenesis of HRS by exacerbating renal dysfunction and systemic vasodilation. Findings indicate that HRS patients exhibit significantly elevated levels of IL-6 and TNF-α, along with increased regulatory T-cell populations and monocyte activation markers. Elevated CRP and procalcitonin levels correlate with worsening renal function, emphasizing the role of systemic inflammation in HRS progression.

Keywords: Hepatorenal syndrome, liver cirrhosis, immunological markers, inflammation, cytokines, endotoxemia, renal dysfunction.

First page

732

Last page

735

For citation:Sanokulova S.A. - IMMUNOLOGICAL INDICATORS OF THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS//New Day in Medicine 4(78)2025 732-735 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. World Health Organization. Global hepatitis report. Geneva, Switzerland; 2017. (Electronic resource). URL: http://www.who.int/hepatitis/publications/global-hepatitis- eport2017/en/ (access date: 11.09.2019).
  2. WHO fact sheet, July 2019. Social aspects of population health. 2019;65(4). (In Russian).
  3. Камилов Ф.Х. и др. Частота встречаемости различных этиологических форм хронических вирусных гепатитов и циррозов печени. Инфекция, иммунитет и фармакология. 2010. (1-2):102-105.
  4. Ахмедова М.Д., Ташпулатова Ш.А., Ихтиярова Г.А., Каримова М.Т. Хронические вирусные гепатиты B и D у беременных: распространенность, течение и исходы (обзор литературы). Журнал инфектологии. 2021;13(2):29-37.
  5. Su, D.H.; Zhuo, C.; Liao, K.; Cheng, W.B.; Cheng, H.; Zhao, X.F. Value of serum procalcitonin levels in predicting spontaneous bacterial peritonitis. Hepato-Gastroenterol. 2013, 60, 641–646.
  6. Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома // Проблемы здоровья и экологии. 2020. №3 (65).
  7. Ibrahim E.-S., Alsebaey A., Zaghla H., Moawad Abdelmageed S., Gameel K., Abdelsameea E. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. Eur. J. Gastroenterol. Hepatol. 2017;29:1247–1250.
  8. Lebrec D., Thabut D., Oberti F., Perarnau J., Condat B., Barraud H., Saliba F., Carbonell N., Renard P., Ramond M., et al. Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients with Advanced Cirrhosis. Gastroenterology. 2010;138:1755–1762.e2.
  9. Amin A.A., Alabsawy E.I., Jalan R., Davenport A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Semin. Nephrol. 2019;39:17–30
  10. He X., Su F., Taccone F.S., Laporte R., Kjølbye A.L., Zhang J., Xie K., Moussa M.D., Reinheimer T.M., Vincent J.-L. A Selective V1A Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock*. Crit. Care Med. 2016;44:23–31.

    file

    download